UNSPSC 51382905: Glucosamine hydrochloride

This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 750W5330FY. European Medicines Agency schedules Glucosamine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02354MIG. Glucosamine hydrochloride generally arises in the molecular formula C6H13NO5.CLH. The term 'glucosamine hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation.

Most nations, for tariff and trade purposes, schedule glucosamine hydrochloride under HS 29329970 and SITC 51569. As of Q4 2014, GLUCOSAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Glucosamine hydrochloride bears US NLM identifiers UMLS ID C0771903 and NCI Concept Code C83732. SMILES: C([C@H]([C@H]([C@@H]([C@H](C=O)N)O)O)O)O.CL.

UNSPSC 51382905 Glucosamine hydrochloride is a Commodity code that shows a significant mismatch between its nominal scope and recent state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, a direct-to-manufacturer prescription program request for information, and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle — none of which center on glucosamine hydrochloride. State and local procurement systems appear to be using this code to classify a broader range of pharmaceutical and over-the-counter health products rather than glucosamine specifically, suggesting either tagging inconsistency or a subordinate category designation within health agencies' internal classification systems.

The issuing bodies span state health departments, county health systems, and multi-state cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries (due July 26, 2023), with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs before launching a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP in January 2026 with a response deadline of March 26, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. Geographic activity centers on Florida, Texas, and the upper Midwest. Vendors pursuing this code should verify internal client-side UNSPSC classification practices, as the tagging signal appears unreliable for narrowly scoped glucosamine procurement.